Figure 2 from Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer

Le résumé fourni par la source

AZ’1569 combined with chemotherapy or cetuximab does not induce apoptosis in KRASG12C MT colorectal cancer cells. A, CTG assays in colorectal cancer cells treated with no drug (control), 5-FU, AZ’1569, or 5-FU in combination with AZ’1569 for 72 hours. CI values were calculated using the method of Chou and Talalay. CI values <1, >1, and equal to 1 indicate synergy, antagonism, and additive effects for the drug combinations, respectively. Dashed lines indicate CI values of 0.3, 0.7, and 1. Representative results of at least three experiments (left). Absolute cell viability for different combinations (right). Dashed line indicates 50% cell viability. B, Colorectal cancer cells were cotreated with AZ’1569 and 5-FU, oxaliplatin, or SN-38 for 48 hours. Top: PARP, caspase 9, caspase 3, caspase 8, and KRAS levels were determined by WB. Bottom: Apoptosis was assessed by caspase 3/7 activity assay. * = nonspecific band. C, CTG cell viability assays in KRASG12C MT colorectal cancer cells cotreated with AZ’1569 and cetuximab for 120 hours. CI values were calculated to evaluate the nature of interaction. D,KRASG12C MT colorectal cancer cells were cotreated with AZ’1569 and cetuximab for 48 hours, apoptosis was assessed by WB analysis for PARP (top) and caspase-3/7 activity assays (bottom). A two-way ANOVA was used to analyze statistical significance.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.